Related Experiment Video
Updated: Jul 5, 2026
11:17
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
Heparin and low-molecular-weight heparin
Elaine Gray1, Barbara Mulloy, Trevor W Barrowcliffe
1National Institute for Biological Standards & Control (NIBSC), Blanche Lane, South Mimms, Potters Bar, Herts EN6 3QG, UK. egray@nibsc.ac.uk
Thrombosis and Haemostasis
|May 2, 2008
Summary
Heparin and low-molecular-weight heparins (LMWH) are crucial for preventing and treating venous thrombosis. LMWH offers improved pharmacokinetics and administration convenience, proving as effective and safe as unfractionated heparin.
Area of Science:
- Pharmacology and Medicine
Background:
- Heparin is a long-established biological medicine for venous thrombosis.
- Low-molecular-weight heparins (LMWH) represent advancements in anticoagulant therapy.
Purpose of the Study:
- To review the chemistry and mechanisms of action of heparin and LMWH.
- To discuss the measurement of anticoagulant activities.
- To outline the clinical status of these anticoagulants.
Main Methods:
- Review of existing literature on heparin and LMWH.
- Analysis of pharmacokinetic and safety data.
- Evaluation of clinical efficacy in various indications.
Main Results:
- LMWH demonstrates superior pharmacokinetic properties and ease of administration compared to unfractionated heparin.
- LMWH is as effective and safe as unfractionated heparin in numerous clinical applications.
- Heparin and LMWH are vital tools in managing thromboembolic disorders.
Conclusions:
- LMWH has largely replaced unfractionated heparin in many therapeutic areas due to its advantages.
- Understanding the properties of heparin and LMWH is essential for optimal patient care.
- Continued research into anticoagulants remains important for improving treatment outcomes.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.